SEARCH

SEARCH BY CITATION

References

  • 1
    Benfield T, Espersen F, Frimodt-Møller N et al. Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin Microbiol Infect 2007; 13: 257263.
  • 2
    Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteraemias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996; 23: 255259.
  • 3
    Hawkins C, Huang J, Noskin GA, Zembower TR, Bolon M. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Int Med 2007; 167: 18611867.
  • 4
    Chang FY, MacDonald BB, Peacock JE Jr et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82: 322332.
  • 5
    Shurland S, Zhan M, Bradham DD, Roghmann MC. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 2007; 28: 273279.
  • 6
    Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26: 166174.
  • 7
    Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36: 5359.
  • 8
    de Kraker ME, Wolkewitz M, Davey PG, Grundmann H, BURDEN Study Group. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 2011; 55: 15981605.
  • 9
    Lambert ML, Suetens C, Savey A et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 2011; 11: 3038.
  • 10
    Huskins WC, Goldmann DA. Controlling methicillin-resistant Staphylococcus aureus, a ‘Superbug’. Lancet 2005; 365: 273275.
  • 11
    Charlson ME, Pompei P, Ales K, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373383.
  • 12
    Knaus WA, Wagner DP, Draper EA et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100: 16191636.
  • 13
    European Centre for Disease Prevention and Control (ECDC) network: HEALTHCARE-ASSOCIATED INFECTIONS. Available at: http://ecdc.europa.eu/en/activities/surveillance/HAI/Documents/2008_HAI_%20special_chapter.pdf (last accessed 8 September 2011).
  • 14
    Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 8thedn. Approved standard. Document M7-A8. Wayne, PA: CLSI; 2009.
  • 15
    European Antimicrobial Resistance Surveillance Network (EARS-Net). EARSS Annual Report 2008. Jan 2008.
  • 16
    Rosenthal V, Maki DG, Salomao R et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med 2006; 145: 582591.
  • 17
    Naimi TS, LeDell KH, Boxrud DJ et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996–1998. Clin Infect Dis 2001; 33: 990996.
  • 18
    Rodríguez-Baño J, López-Prieto MD, Portillo MM et al. Epidemiology and clinical features of community-acquired, healthcare associated and nosocomial bloodstream infections in tertiary and community hospitals. Clin Microbiol Infect 2009; 15: 11111118.
  • 19
    Fatkenheuer G, Preuss M, Salzberger B et al. Long-term outcome and quality of care of patients with Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2004; 23: 157162.
  • 20
    Kaech C, Elzi L, Sendi P et al. Course and outcome of Staphylococcus aureus bacteraemia: a retrospective analysis of 308 episodes in a Swiss tertiary-care centre. Clin Microbiol Infect 2006; 12: 345352.
  • 21
    Soriano A, Martinez JA, Mensa J et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000; 30: 368373.
  • 22
    Kim SH, Park WB, Lee KD et al. Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis 2003; 37: 794799.
  • 23
    Kang CI, Song JH, Chung DR et al. Clinical impact of methicillin resistance on outcome of patients with Staphylococcus aureus infection: a stratified analysis according to underlying diseases and sites of infection in a large prospective cohort. J Infect 2010; 61: 299306.
  • 24
    Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36: 14181423.
  • 25
    Gomez J, Garcıa-Vazquez E, Banos R et al. Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy. Eur J Clin Microbiol Infect Dis 2007; 26: 239245.
  • 26
    Schramm GE, Johnson JA, Doherty JA, Micek ST, Kollef MH. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 2006; 34: 20692074.
  • 27
    Paul M, Kariv G, Goldberg E et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2010; 65: 26582665.
  • 28
    Hope R, Livermore DM, Brick G, Lillie M, Reynolds R, BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001–06. J Antimicrob Chemother 2008; 62 (suppl 2): ii65ii72.
  • 29
    Jacobsson G, Dashti S, Wahlberg T, Andersson R. The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western Sweden. Scand J Infect Dis 2007; 39: 613.
  • 30
    Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000–2006. J Infect Dis 2008; 198: 3364.
  • 31
    Manzur A, Dominguez MA, Ruiz de Gopegui E et al. Natural history of methicillin-resistant Staphylococcus aureus colonisation among residents in community long term care facilities in Spain. J Hosp Infect 2010; 76: 215219.